Back to Search Start Over

Neurocognitive function and survival in children with average-risk medulloblastoma treated with hyperfractionated radiation therapy alone: Long-term mature outcomes of a prospective study.

Authors :
Gupta, Tejpal
Kalra, Babusha
Goswami, Savita
Deodhar, Jayita
Rane, Pallavi
Epari, Sridhar
Moiyadi, Aliasgar
Dasgupta, Archya
Chatterjee, Abhishek
Chinnaswamy, Girish
Source :
Neuro-Oncology Practice; May2022, Vol. 9 Issue 3, p236-245, 10p
Publication Year :
2022

Abstract

Background The purpose of this study was to report long-term neurocognitive and clinical outcomes in children treated for average-risk medulloblastoma with hyperfractionated radiation therapy (HFRT) alone. Methods Between 2006 and 2010, 20 children with rigorously staged average-risk medulloblastoma were treated on a prospective study with HFRT without upfront adjuvant systemic chemotherapy after written informed consent. HFRT was delivered as twice-daily fractions (1 Gy/fraction, 6–8 hours apart, 5 days/week) to craniospinal axis (36 Gy/36 fractions) plus conformal tumor-bed boost (32 Gy/32 fractions). Neurocognitive function was assessed at baseline and periodically on follow-up using age-appropriate intelligence quotient (IQ) scales. Results Median age was 8 years (range 5–14 years) with 70% being males. Mean and standard deviation (SD) scores at baseline were 90.5 (SD = 17.08), 88 (SD = 16.82) and 88 (SD = 17.24) for Verbal Quotient (VQ), Performance Quotient (PQ), and Full-Scale IQ (FSIQ) respectively. Mean scores remained stable in the short-to-medium term but declined gradually beyond 5 years with borderline statistical significance for VQ (P =.042), but nonsignificant decline in PQ (P =.259) and FSIQ (P =.108). Average rate of neurocognitive decline was <1 IQ point per year over a 10-year period. Regression analysis stratified by age, gender, and baseline FSIQ failed to demonstrate any significant impact of the tested covariates on longitudinal neurocognitive function. At a median follow-up of 145 months, 10-year Kaplan-Meier estimates of progression-free survival and overall survival were 63.2% and 74.1% respectively. Conclusion HFRT alone without upfront adjuvant chemotherapy in children with average-risk medulloblastoma is associated with modest decline in neurocognitive functioning with acceptable long-term survival outcomes and may be most appropriate for resource-constrained settings. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20542577
Volume :
9
Issue :
3
Database :
Complementary Index
Journal :
Neuro-Oncology Practice
Publication Type :
Academic Journal
Accession number :
157074172
Full Text :
https://doi.org/10.1093/nop/npac020